Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02188160 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 2 study, sponsored by Kala Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT02188160 is a Phase 2 study that has completed, run by Kala Pharmaceuticals. The registered enrollment target is 150 participants.
The verdict
NCT02188160, a Phase 2 study, has completed, sponsored by Kala Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 28 days, with 1-2 drops instilled in each eye four times daily (QID).
Interventions
- DRUG Placebo
- DRUG KPI-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02188160
The ClinicalTrials.gov registry entry for NCT02188160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kala Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02188160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02188160 about?
NCT02188160 is a clinical study titled "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease". The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 28 days, with 1-2 drops instilled in each eye four ...
What is the current status of trial NCT02188160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2014-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02188160?
The interventions under investigation include: Placebo (DRUG), KPI-121 (DRUG).
Who is sponsoring clinical trial NCT02188160?
This trial is sponsored by Kala Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.